In this study, the inhibition of IL-4/IL-13 signaling through dupilumab treatment significantly improved AD signs and symptoms and induced a progressive shift of AD molecular phenotype from lesional to nonlesional skin [27]. This evidence concerns the gene IL4 and Alzheimer disease.